Keywords: Fibrosis-4 Index (FIB-4), Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA), Insulin Resistance, Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Resmetirom, Semaglutide
Introduction
Metabolic dysfunction-associated steatotic liver disease (MASLD) has quietly become one of the defining chronic diseases of the metabolic era. Once dismissed as an incidental finding on abdominal imaging, it is now understood as the hepatic expression of the same insulin resistance, visceral adiposity, and dysglycemia that drive type 2 diabetes (T2D) and cardiovascular disease. Global adult prevalence is estimated at roughly 38%, with projections exceeding 55% by 2040 if current metabolic trends continue, making MASLD, in effect, the liver manifestation of a much larger cardiometabolic epidemic [1].
The period spanning late 2025 through 2026 has been unusually consequential for the field. A settled, cardiometabolically grounded nomenclature has matured into routine clinical use; several major hepatology societies issued or updated evidence-based practice guidelines; the first disease-modifying pharmacotherapies moved from pivotal trial data into practice guidance; and noninvasive, scalable diagnostic pathways have begun displacing biopsy-first paradigms. Taken together, these developments mark what many clinicians are now calling an inflection point, the moment MASLD shifted from a diagnosis of exclusion, managed by watchful waiting, to a screenable, stratifiable, and increasingly treatable disease.
This review synthesizes the 2026 state of the field for clinicians, researchers, and preventive-health innovators: the completed nomenclature transition, the current epidemiological burden, the updated diagnostic and risk-stratification landscape, the new therapeutic armamentarium, the disease’s extrahepatic and cardiometabolic reach, and the enduring role of lifestyle medicine. We close by considering what this update means for longevity- and prevention-oriented clinical practice, where MASLD is increasingly recognized as a high-value target for early, data-driven intervention.
Completing the Nomenclature Transition: From NAFLD to MASLD/ MASH
In June 2023, a multisociety Delphi consensus process, spanning AASLD, EASL, and other regional liver associations, formally replaced “nonalcoholic fatty liver disease” (NAFLD) with “metabolic dysfunction-associated steatotic liver disease” (MASLD), and “nonalcoholic steatohepatitis” (NASH) with “metabolic dysfunction-associated steatohepatitis” (MASH). The rationale was twofold: to remove stigmatizing and clinically imprecise language built around the exclusion of alcohol use, and to anchor diagnosis in the presence of positive, measurable cardiometabolic criteria rather than a diagnosis reached only after ruling other conditions out. This built on an earlier 2020 proposal for “metabolic associated fatty liver disease” (MAFLD), which first argued for a positive, criteria-based diagnostic approach [2,3].
Under the current definition, MASLD requires hepatic steatosis on imaging or histology plus at least one of five cardiometabolic risk factors: elevated body mass index or waist circumference, prediabetes or T2D, hypertension, hypertriglyceridemia, or low HDL cholesterol. A related category, MetALD, was created for individuals with overlapping metabolic risk and moderate alcohol intake, replacing the previous binary alcohol-related/non-alcohol-related split. By 2026, this nomenclature is essentially settled across hepatology, and it is now embedded in the guideline language of the Japanese Society of Gastroenterology, the joint EASL-EASD-EASO guidelines, and Italy’s AISF pharmacological guidance. Adoption outside hepatology, in primary care, endocrinology, and cardiology documentation continues to catch up, which remains a practical barrier to consistent screening referral pathways [2,4,5,11].
The Scale of The Problem: MASLD Epidemiology in 2026
MASLD is now the most common chronic liver disease worldwide. Current estimates place adult prevalence at approximately 38%, with 7–14% prevalence already present in children and adolescents. A 2026 systematic review, meta-analysis, and modelling study focused specifically on the 5–24-year-old population estimated a pooled global prevalence of 7.0% (95% CI, 4.1–11.7), translating into an estimated 340.2 million affected children and adolescents in 2020, up from 118.9 million in 2000 with projections reaching 405.5 million by 2050. Prevalence rose consistently with age and was higher in males across all regions studied. Notably, the same modelling projects that Africa will surpass Asia in absolute pediatric case numbers from 2040 onward, signaling a shifting global burden that has direct implications for where prevention infrastructure will be needed most [1,6].
The clinical consequences of this scale are substantial. MASLD has become a leading indication for liver transplantation in the United States, particularly among women, and a growing contributor to hepatocellular carcinoma (HCC) and cirrhosis case volume. Yet liver-specific outcomes are, for most patients, not the dominant threat: cardiovascular disease remains the single most common cause of death across the MASLD spectrum, and the disease independently correlates with elevated risk of type 2 diabetes, chronic kidney disease, sarcopenia, and several extrahepatic cancers, alongside measurable reductions in quality of life and work productivity1. Without intensified global prevention efforts, incidence is projected to continue rising in parallel with obesity and T2D trends [1].
Diagnosis and Risk Stratification: The 2026 Guideline Landscape
2026 brought a fresh wave of evidence-based clinical practice guidance. The Japanese multisociety guideline, published in Hepatology Research, reaffirmed the Fibrosis-4 (FIB-4) index as the recommended first-line, low-cost noninvasive stratification tool, reserving elastography-based methods (vibration-controlled transient elastography or magnetic resonance elastography) for indeterminate or high-risk results. This tiered approach was echoed in the 2024 EASL-EASD-EASO guidelines and reinforced operationally by AASLD’s November 2025 update to its MASLD practice guidance, which incorporated the latest trial data into practical criteria for patient selection, comorbidity management, and safety monitoring around newly available pharmacotherapy [4,5,7].
Liver biopsy, still the reference standard for confirming at-risk MASH and for histologic fibrosis staging using validated scoring system is increasingly reserved for cases of genuine diagnostic uncertainty or for clinical-trial enrollment, as composite noninvasive scores mature. The FibroScan-AST (FAST) score, which combines liver stiffness measurement with controlled attenuation parameter and serum AST, was validated as a way to identify patients with both significant necroinflammatory activity and clinically meaningful fibrosis without biopsy. Across the 2026 guideline updates, advanced fibrosis (stage F2–F3) is repeatedly identified as the single strongest determinant of liver-related morbidity and mortality in MASLD, which has pushed diagnostic pathways further toward risk-based triage rather than biopsy-first algorithms, a shift with direct relevance for scalable, population-level screening models [4,8,9].
The Therapeutic Revolution: From Lifestyle-Only to Disease-Modifying Drugs
For decades, lifestyle modification was the only tool available for MASLD/MASH, with no approved disease-modifying pharmacotherapy. That changed in 2024 with the approval of resmetirom, a liver-directed thyroid hormone receptor-beta agonist and the first FDA-approved MASH-targeted medication for patients with stage 2–3 fibrosis. In the pivotal phase 3 MAESTRO-NASH trial, resmetirom produced significantly higher rates of MASH resolution without fibrosis worsening, and fibrosis improvement without MASH worsening, compared with placebo, alongside favorable effects on atherogenic lipids. Longer-term data from the MAESTRO-NASH-OUTCOMES program, evaluating resmetirom in compensated MASH cirrhosis, continued to mature through 2026 and is shaping discussion of an expanded indication [1,10].
The second major advance came from the incretin class. The phase 3 ESSENCE trial enrolled 800 patients with biopsy-confirmed MASH and stage 2–3 fibrosis across 253 sites in 37 countries, treating them with semaglutide for up to 240 weeks. At the primary analysis, 62.9% of semaglutide-treated patients achieved MASH resolution without worsening fibrosis versus 34.3% on placebo; 36.8% achieved fibrosis improvement without worsening MASH versus 22.4% on placebo; and 32.7% achieved both endpoints simultaneously versus 16.1% on placebo (P<0.001 for all comparisons), accompanied by a mean body-weight reduction of 10.5% versus 2.0%. These results directly informed AASLD’s November 2025 practice guidance update, which now integrates semaglutide alongside resmetirom into individualized treatment algorithms for MASH with moderate-to-advanced fibrosis. Additional incretin-class and dual/triple agonist candidates continue to move through late-stage development, reflecting an accelerating convergence of hepatology and obesity medicine [7,12].
Society guidance issued in 2026, including AISF’s pharmacological treatment update, now frames therapy selection as a sequencing and pairing decision rather than a single-drug choice: pharmacotherapy is considered for patients with probable at-risk MASH, with agent selection informed by fibrosis stage, cardiometabolic comorbidity burden, and patient preference, always layered on top of, rather than substituted for, lifestyle intervention [4,11].
Beyond the Liver: Cardiometabolic, Renal, and Oncologic Risk
For most people living with MASLD, the disease’s true burden is cardiometabolic and oncologic as much as it is hepatic. Cardiovascular disease remains the leading cause of death across the MASLD spectrum, ahead of liver-specific mortality in most cohorts. The relationship with type 2 diabetes is bidirectional and mutually reinforcing: metabolic dysregulation drives hepatic steatosis, while the presence of MASLD in patients with T2D is associated with a higher burden of advanced fibrosis and worse overall outcomes [1].
Hepatocellular carcinoma risk, while concentrated in patients with cirrhosis, is also observed in noncirrhotic MASLD, prompting continued interest in refining risk-stratified surveillance strategies rather than applying uniform screening across the whole population. Chronic kidney disease, sarcopenia, and several extrahepatic cancers further compound morbidity as patients age, underscoring that MASLD functions less as an isolated organ-specific disease and more as a systemic marker of accumulated cardiometabolic risk, precisely the kind of multisystem signal that longevity- and prevention-focused risk models are designed to capture [1].
Lifestyle Medicine: Still the Foundation of Care
Despite the arrival of effective pharmacotherapy, every major 2026 guideline retains lifestyle modification, generally targeting 7–10% total body weight loss, as first-line and adjunct therapy for MASLD/MASH. A 2025 systematic review and meta-analysis of 37 randomized controlled trials (11 evaluating the Mediterranean diet, 27 evaluating exercise, and 2 evaluating combined interventions) quantified these effects directly: the Mediterranean diet alone reduced body weight by roughly 2.4 kg, BMI by 0.7 kg/m², waist circumference by 1.6 cm, and ALT by approximately 4.0 IU/L relative to controls, while aerobic exercise, alone or combined with resistance training, produced comparable or greater reductions in body weight and, for resistance training specifically, a larger ALT reduction of roughly 15.4 IU/L. The authors concluded that Mediterranean-style diet and aerobic exercise, whether alone or combined with resistance training, support weight loss and measurably improve liver health in MASLD/MASH [4,5,13].
These effect sizes, while individually modest compared with pharmacotherapy, remain clinically important for two reasons: they are additive with drug treatment, and they represent the necessary behavioral substrate for maintaining benefit, given the risk of weight regain and metabolic relapse after pharmacologic discontinuation. No 2026 guideline proposes lifestyle intervention as an alternative to pharmacotherapy in at-risk MASH, only as its irreplaceable foundation [4,11].
Implications for Longevity and Preventive Health Practice
MASLD is, in many ways, a paradigm case for why cardiometabolic disease demands integrated, whole-body prevention rather than siloed, single-organ management. It is silent in its early stages, extremely common, closely tied to modifiable risk factors, and now, for the first time, pharmacologically actionable well before end-stage liver disease develops. Three 2026 shifts are particularly relevant for AI-enabled longevity and preventive-health platforms.
First, noninvasive risk stratification, FIB-4 as a first-line filter, elastography for indeterminate cases, and a fast-growing set of composite and AI/ML-assisted biomarker scores is displacing biopsy-first pathways. This creates a genuine opportunity to embed scalable, low-friction MASLD screening directly into routine metabolic health check-ups, rather than treating it as a separate hepatology referral. Second, the five-criteria cardiometabolic definition of MASLD makes it a natural companion diagnosis to existing metabolic syndrome, prediabetes, and obesity-management protocols: any platform already tracking BMI, waist circumference, blood pressure, triglycerides, and HDL is, in effect, already halfway to a MASLD risk flag. Third, the arrival of effective pharmacotherapy shifts the clinical imperative from passive, watchful monitoring to early identification and intervention — directly mirroring the broader longevity-medicine thesis of intercepting disease trajectories years or decades before a clinical event occurs [2,4,8,9,10,12].
For research and development teams working at the intersection of AI and preventive medicine, near-term opportunities include validating AI-assisted noninvasive fibrosis scoring against FIB-4 and elastography in real-world longitudinal cohorts, integrating MASLD risk flags into existing metabolic-health dashboards alongside diabetes and cardiovascular risk scores, and studying how combined lifestyle and pharmacotherapy protocols might be matched to individual metabolic phenotypes rather than applied uniformly.
Conclusion
2026 marks a genuine inflection point for metabolic dysfunction-associated steatotic liver disease. A settled, cardiometabolically grounded nomenclature has matured into routine use; updated multisociety guidelines have refined noninvasive diagnostic pathways; and, for the first time, disease-modifying pharmacotherapies backed by robust phase 3 evidence are available for patients with at-risk MASH. Yet the disease’s true burden remains as much cardiometabolic and oncologic as hepatic, and lifestyle intervention remains the non-negotiable foundation of every guideline-based treatment pathway. For clinicians, researchers, and longevity-medicine innovators alike, MASLD can no longer be treated as a low-priority diagnosis of exclusion. It is a screenable, stratifiable, and increasingly treatable disease that belongs at the center of any serious metabolic-disease prevention strategy [1,2,4,5,7,10-13].
Reference
1. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32-50.
2. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86.
3. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.
4. Akuta N, Kogiso T, Ikejima K, Otsuka M, Kawaguchi T, Kawanaka M, et al. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. Hepatol Res. 2026;56(6):887-902.
5. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542.
6. Liu Y, Cai S, Yang R, Lin J, Dang J, Huang T, et al. Global and regional prevalence, burden, and risk factors for MASLD in children and adolescents aged 5 to 24 years: a systematic review, meta-analysis, and modeling study. BMC Med. 2026;24:267.
7. Bansal MB, Patton H, Morgan TR, Carr RM, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025 Nov 11. Epub ahead of print.
8. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
9. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362-73.
10. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497-509.
11. Associazione Italiana per lo Studio del Fegato (AISF). AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): a 2026 update. Dig Liver Dis. 2026. Epub ahead of print.
12. Sanyal AJ, Newsome PN, Kliers I, Ostawal A, Yu ES, Iwamoto M, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089-99.
13. Beigrezaei S, et al; GRIPonMASH Consortium. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2025;23:502.